

1 Title: Antimicrobial and anti-inflammatory activity of Cystatin C on human gingival fibroblast
2 incubated with *P. gingivalis*

3

4 B.E. Blancas Luciano¹, I. Becker², J. Zamora Chimal², J. Delgado Domínguez², A. Ruíz
5 Remigio², E.R. Leyva-Huerta,³ J.Portilla-Robertson,³ A.M. Fernández-Presas^{1,4*}

6

7 ¹Departamento de Microbiología y Parasitología, Facultad de Medicina, Av. Universidad 3000,
8 Col. Universidad Nacional Autónoma de México, CP 04510, Mexico City, Mexico

9 ²Unidad de Investigación en Medicina Experimental, Universidad Nacional Autónoma de
10 México, Hospital General de México, Dr. Balmis, 148 Col. Doctores, Del. Cuauhtémoc, C.P.
11 06726, Mexico City,

12 ³Departamento de Medicina Oral y Pathología, Division de Posgrado, Facultad de Odontología,
13 Universidad Nacional Autónoma de México, CP 04510, Mexico City, Mexico

14 ⁴ Centro de investigación en Ciencias de la Salud (CICSA), FCS, Universidad Anahuac México
15 Campus Norte, Huixquilucan, Mexico

16

17 Corresponding Author:

18 Ana María Fernández Presas

19 Av. Universidad 3000, Col. Universidad Nacional Autónoma de México, CP 04510, Mexico City,
20 Mexico

21 Email address: presas@unam.mx

22

23 Abstract

24

25 **Background.** Periodontal disease is considered one of the most prevalent chronic infectious
26 diseases, often leading to the disruption of tooth-supporting tissues, including alveolar bone,
27 causing tooth mobility and loss. *Porphyromonas gingivalis* is considered the major etiological
28 agent of this disease, having a plethora of virulence factors, including, lipopolysaccharides,
29 hemolysins, and proteinases. Antimicrobial peptides are one of the main components of the innate
30 immune response that inhibit the growth of *P. gingivalis*. The aim of this study was to analyze the
31 antimicrobial activity of Cystatin C and to assess the effect on the inflammatory and anti-
32 inflammatory cytokines, the production of reactive oxygen species, and in the release of nitric
33 oxide by human gingival fibroblasts incubated with *P. gingivalis* in the presence and absence of
34 cystatin C.

35 **Methods.** *P. gingivalis* ATCC 33277 was exposed to cystatin C for 24h and co-cultured with
36 human gingival fibroblasts (HGFs) ATCC CRL-2014. The effect of cystatin on growth of *P.*

Eliminó: effect

38 *gingivalis* and HGFs was evaluated. Pro-inflammatory (TNF α , IL-1 β) and anti-inflammatory (IL-
39 10) cytokines were determined by ELISA in the supernatants of HGFs incubated with *P. gingivalis*
40 exposed to cystatin C. Additionally, nitrites and reactive oxygen species (ROS) production were
41 evaluated.

42 **Results.** Cystatin C inhibited the growth of *P. gingivalis* without affecting HGFs. Incubation of
43 HGFs with *P. gingivalis* led to a significant increase of TNF- α and IL-1 β . In contrast, HGFs
44 incubated with *P. gingivalis* exposed to cystatin C showed a decreased production of both
45 cytokines, whereas IL-10 was enhanced. Incubation of HGFs with *P. gingivalis* led to an increased
46 NO and ROS production, which was reduced in the presence of the peptide.

47 **Conclusions.** Cystatin C inhibits the growth of *Porphyromonas gingivalis* and decreases the
48 inflammatory cytokines, ROS, and NO production during infection of HGFs with *P. gingivalis*.
49 Knowledge on the antimicrobial and immunomodulatory properties of cystatin C could aid in the
50 design of new therapeutic approaches to facilitate the elimination of this bacterium to improve the
51 treatment of periodontal disease.

52

53 **Introduction**

54

55 Periodontitis is a chronic infectious disease, characterized by an exacerbated inflammatory
56 response and progressive loss of tooth supporting tissues (Könönen et al., 2019) *Porphyromonas*
57 *gingivalis* is a **periodontal pathogen** bacterium implicated as a major, etiological agent in
58 periodontitis (van Winkelhoff et al., 2002). This bacterium has been recovered from periodontal
59 pockets in a high percentage (75.8%) of patients with periodontitis (Rafiei et al., 2017).

60 The most abundant cell types in periodontal connective tissues are gingival fibroblasts (GF),
61 where they participate in the repair of periodontal tissues during inflammatory periodontal
62 diseases (Lee, et al., 2013). GF also promotes periodontal wound healing (Smith et al., 2019;
63 Baek et al., 2013).

Eliminó: periodontopathogen

Eliminó: 2

66 Furthermore, LPS of *P. gingivalis* increases their superoxide concentrations after exposure to
67 human gingival fibroblasts (HGFs) (Gözl et al., 2014). Thus, these cells can also participate in
68 the progression of periodontitis, inducing the release of inflammatory such as nitric oxide,
69 cytokines, reactive oxygen species (ROS), and nitric oxide (How et al., 2016; Kirkwood et al.,
70 2007; Gözl et al., 2014; Herath et al., 2016).

71 Cytokines are involved in the initiation and progression of periodontal disease (Ramadan et
72 al., 2020). Even though secreted cytokines promote the elimination of bacteria, the
73 overproduction of pro-inflammatory cytokines may participate directly in periodontal
74 breakdowns, such as the breakdown of collagen periodontal attachment loss, and alveolar bone
75 resorption (Gabay, Lamachia & Palmer, 2010). TNF- α and IL-1 β are the major secreted pro-
76 inflammatory cytokines, that are important markers of periodontitis progression and severity. and
77 they are also the main inducers of effector molecules that cause the breakdown of periodontal
78 tissues (Gomes et al., 2016). TNF- α and IL-1 β are produced by several cell types including
79 dendritic cells, macrophages, periodontal ligament cells, osteoblasts, and gingival fibroblasts and
80 can act as multifunctional molecules (Cheng et al., 2020). IL-1 β promotes production of
81 metalloproteinases (MMPs), which are involved in the extracellular matrix degradation and, in
82 turn, bone resorption and periodontal tissue destruction (Aleksandrowicz et al., 2021). TNF- α ,
83 participates in the bone resorption process, inducing receptor activators for nuclear factor- κ B
84 (RANK) expression in osteoclast precursors and RANKL expression in osteoblast (Pan, Wang &
85 Chen, 2019). In addition, TNF- α and IL-1 β also induce reactive oxygen species (ROS)
86 generation in periodontal tissue (Wang et al., 2014), where oxidative stress has been shown to be
87 involved in periodontitis (Tomofuji et al., 2006; Maruyama et al., 2011). These pro-inflammatory
88 mediators are required for the immune defense against bacteria, yet their uncontrolled activity
89 leads the accumulation of ROS (superoxide radicals, hydrogen peroxide, hydroxyl radicals and
90 singlet oxygen) (Gözl et al., 2014). Even though these products stimulate proliferation and
91 differentiation of cultured human periodontal ligament fibroblasts at low concentrations, their
92 presence in higher concentrations can induce pathogen killing and cytotoxic effects on
93 periodontal tissues and pathogen killing (Chapple & Matthews 2007), Zhu et al. (2020)
94 demonstrated that after the stimulation of HGFs with LPS, ROS production in mitochondria
95 (mtROS) were significantly enhanced these results indicate that oxidative stress can be induced
96 during periodontitis (Liu et al., 2021). It is noteworthy that *P. gingivalis* is resistant to oxidative

Comentado [LELJ1]: To define

Eliminó: *Porphyromonas*

Eliminó: the

Con formato: Sin viñetas ni numeración

Eliminó: (Staudte et al., 2010;

Comentado [LELJ2]: To define

Eliminó: mediators

Comentado [LELJ3]: Repeated (line 68)

Eliminó:

Comentado [LELJ4]: Still not clear. Line 81 metalloproteinases, line 110 matrix metalloproteinases, please could you homogenize acronyms.

Eliminó:

Eliminó:

Eliminó:

Eliminó: was

Eliminó: ,

Eliminó: ,

108 burst killing due to its antioxidant enzymes, such as thiol peroxidases and rubrerythrin.
 109 Furthermore, these bacteria accumulate a hemin layer on the cell surface that protects the
 110 bacteria from oxidative stress (Wang et al., 2014; Henry, McKenzie, Robles & Fletcher, 2012).
 111 On the other hand, IL-10, an anti-inflammatory cytokine that suppresses the inflammatory
 112 responses (Al-Rasheed et al., 2003), also protects from tissue destruction by inhibiting both
 113 matrix metalloproteinases (MMPs) and receptor activators for nuclear factor-kB (RANK)
 114 systems, leading to the differentiation and activation of osteoclasts (Garlet et al., 2006).
 115 Stimulation with bacteria or bacterial components like LPS induce the production of
 116 inflammatory cytokines, such as interleukin 1, -6, -8, and nitric oxide (NO), in human
 117 monocytes, endothelial cells, macrophages, and gingival fibroblasts (Gutierrez-Venegas et al.,
 118 2005; Staudte et al., 2010; Gölz et al, 2014). *P. gingivalis* triggers the production of NO by
 119 activating the expression of inducible nitric oxide synthases (NOS) (Sun, et al. 2010; Brennan,
 120 Thomas, & Langdon, 2003). It is noteworthy that it can resist NO stress and maintain nontoxic
 121 intracellular NO concentrations (Zumf, 2002). Thus, a high concentration of NO fails to
 122 eliminate this bacterium, yet it can exert a deleterious effect on the periodontal tissue, favoring
 123 vasodilation and diminishing platelet aggregation, which contributes to gingival bleeding. These
 124 toxic effects on the surrounding tissue increase the severity of periodontitis (Boutrín et al., 2012).
 125 It has been suggested that the inducible nitric oxide synthase (iNOS) may be involved in
 126 periodontal disease (Batista et al., 2002), because usually, periodontal pathogenic bacteria
 127 increase the production of iNOS, including HGFs (Sosroseno, et al., 2009).
 128 Furthermore, cytokines and chemokines produced by gingival fibroblasts in response to *P.*
 129 *gingivalis* infection could increase and their effects on leukocytes are modulated by the
 130 enzymatic activity of *P. gingivalis*-derived proteinases, that cleave and disrupt their functions
 131 (Calkins et al. 1998; Kobayashi, Isogi & Hirose 2003; Palm, Khalaf & Bengtsson, 2015). The
 132 production of *P. gingivalis* cysteine proteinases are associated with the growth and establishment
 133 of *P. gingivalis*, they are divided into arginine-specific (Rgp) and lysine-specific (Kgp)
 134 proteinases. Additionally, these cysteine proteases exert potent immunomodulatory effects on
 135 human gingival fibroblasts. The main causative factor of tissue damage involved in the disease
 136 progression, could be the gingipains of the bacterium, even though *P. gingivalis* is considered an
 137 opportunistic pathogen. Thus, control of proteolytic enzymes of *P. gingivalis* could represent an
 138 interesting target for the treatment of periodontitis (Torbjörn, Atika & Hazem, 2015).

Eliminó: ,

Eliminó:

Eliminó: ,

Comentado [LELJ5]: Previously described

Comentado [LELJ6]: Previously described

Comentado [LELJ7]: TO define

Comentado [LELJ8]: To check line 68

Eliminó: syntase

Eliminó: pathogenesis

Eliminó: since common

Eliminó: ns can induce the expression

Eliminó: in various host cells

Eliminó: Additionally

Eliminó: ,

Eliminó: expressed

Eliminó: can accumulate

Eliminó: subsequent action

Eliminó:

Eliminó: is

Eliminó: due to

Eliminó: inhibit

Eliminó: biological properties

Eliminó: .

Eliminó: .

Eliminó:

Eliminó:

Eliminó:

162 Antimicrobial peptides (AMPs) are part of the innate defense system in the oral cavity, where
163 cystatins play an important role. Cystatin C belongs to the type 2 family of the cystatin
164 superfamily, it is ubiquitously distributed in plants and animals (Shamsi & Bano, 2017). In the
165 parotid gland of humans, it is present in saliva at a concentration of 0.9 µg/mL (Gorr, 2012). The
166 main function of cystatin C is the inhibition of cysteine proteases by binding to their active sites
167 (Palm, Khalaf & Bengtsson, 2015). It also exerts several immunomodulatory functions and
168 possesses the ability to regulate innate immune responses (Vray, Hartmann & Hoebeke, 2002).
169 The aim of this study was to assess the effect that cystatin C exerts on cytokine production, NO
170 and ROS production by human gingival fibroblasts incubated with *P. gingivalis* in order to be
171 able to evaluate its potential therapeutic use against one of the main etiological agents causing
172 periodontitis, as well as its potential impact on the severity of periodontal disease.

Eliminó:

Eliminó:

Eliminó:

174 Materials & Methods

176 Cells culture

177 Human gingival fibroblasts (HGFs) (ATCC, CRL-2104) were seeded at a density of 5×10^3
178 cells/cm² and cultured in 75 cm² culture flasks in water-saturated atmosphere at 37°C plus
179 5% CO₂ and maintained in Dulbecco's modified Eagle high glucose medium (Sigma Aldrich,
180 Saint Louis, MO, USA), supplemented with 10% fetal bovine serum (GIBCO BRL,
181 Gaithersburg, MD, USA), containing 10 U penicillin plus 25 µg streptomycin /mL (Sigma
182 Aldrich). The fibroblasts were cultured to confluence, at a density of 2.5×10^5 cells/mL, washed
183 twice with phosphate-buffered saline, and dissociated with 0.25% trypsin and 1 mM EDTA for 5
184 min at 37°C, 5% CO₂ (Sigma Aldrich, Saint Louis, MO, USA). The cells were used at passages
185 3-7.

Comentado [LELJ9]: Previously described in line 67

Eliminó:

Eliminó:

Eliminó:

Eliminó: per

Eliminó:

Eliminó:

Eliminó: at

Eliminó:

Eliminó: and

Comentado [LELJ10]: DMEM

Eliminó: /

Eliminó:

187 Bacterial growth

189 *P. gingivalis* strain ATCC 33277 was cultured in brain-heart-infusion and in broth-heart-brain
190 extract (BHI; BD Bioxon, Milan, Italy) containing 5 µg/mL of hemin (Sigma-Aldrich, Munich,
191 Germany) supplemented with 1 µg/mL of menadione (Sigma-Aldrich) cultured at 37°C for 24 h
192 in anaerobic conditions, using the BBL-GasPak jar system (BD Biosciences).

Eliminó:

Eliminó: and

Eliminó: under

Eliminó: robiosis

Eliminó: anaerobic

Eliminó: .

Eliminó:) at 37°C for 24 h

214 After cultivation for 24 h, bacteria were recovered by centrifugation (10 min at 10000 rpm),
 215 washed and resuspended in Krebs-Ringer-Glucose (KRG) buffer (120 mM NaCl, 4.9 mM KCl,
 216 1.2 mM MgSO₄, 1.7 mM KH₂PO₄, 8.3 mM Na₂HPO₄, 10 mM glucose, and 1.1 mM CaCl₂, pH
 217 7.3). Bacterial growth was monitored spectrophotometrically (Jenway Genova R0027, Fischer
 218 Scientific, USA) at 675 nm. The bacterial density was visually adjusted to a turbidity of 0.5
 219 McFarland (1 × 10⁸ colony-forming units (CFU/mL) (Mc Farland, 1907 Emani et al., 2014)).
 220 Ethical approval was given by the Ethics Committee of the School of Medicine (UNAM) with
 221 reference number C54-11.

- Eliminó:
- Eliminó: of culturing
- Eliminó: harvested
- Eliminó: for
- Eliminó: and then
- Eliminó:
- Eliminó:
- Eliminó:
- Eliminó: ;

223 **Antibacterial assay**

224 Lyophilized cystatin C was obtained from *Pichia Pastoris* (Sigma Aldrich, St. Louis, MO) and
 225 reconstituted in Tris Base NaCl Buffer (pH 7.4). Minimum inhibitory concentrations (MIC) of
 226 Cystatin C were determined using the microdilution method in 96-well microtiter plates (Costar,
 227 Corning Life Sciences) (Eloff, 1998; Jadaun et al., 2007). Briefly, an inoculum of *P. gingivalis*
 228 (1 × 10⁶ CFU/mL) containing KRG Buffer was placed in each well. Subsequently, different cystatin
 229 C concentrations (0.1, 0.3, 0.5, 0.7, 0.9 µg/mL) were incubated with the bacteria for 1, 12, 24, and
 230 48 h, under anaerobiosis conditions at 37°C. After the incubation period, 20 µL of Presto Blue Cell
 231 Viability Reagent (Invitrogen, Thermo Fisher Scientific) per well were added. The plates were
 232 incubated for 30 min at 37°C in the dark. Finally, the plates were read in a microplate reader
 233 (Multiskan SkyHigh Microplate Spectrophotometer) at a 675 nm wavelength.

- Comentado [LELJ11]: Some times is written such as Sigma Aldrich and other ones such as Sigma Aldrich, St. Louis, MO, please , to define.
- Eliminó:
- Eliminó: C
- Comentado [LELJ12]: Same case, sometimes such Cystatin and other such cystitis. To homogenize
- Eliminó: was
- Eliminó:
- Eliminó:
- Eliminó:
- Eliminó: ,
- Eliminó: ,

235 **Cell Viability assay**

236 HGFs were seeded at a density of 1 × 10⁵ cells/well in 24-well plates for 24 h, at 37°C with 5%
 237 CO₂. Different concentrations of cystatin C (0.1, 0.3, 0.5, 0.7, 0.9 µg/ml) were added and incubated
 238 for 24 h. After incubation time, 25 µl of XTT/PBS solution (4 mg/4ml) were added per well, for
 239 40 minutes at room temperature, in the dark. Subsequently, microplate plates were read at a
 240 wavelength of 450 nm in a microplate spectrophotometer (Multiskan SkyHigh Microplate
 241 Spectrophotometer).

- Comentado [LELJ13]: This, clearly, is not a MIC, that was why I asked about differences between MIC and MBC since this kind of experiments are able to evaluate viability, then is a minimal bactericidal concentrations, again, MICs are visual. Mandatory to have clear these differences.
- Eliminó: ,
- Eliminó:
- Eliminó: C
- Dio formato: Subíndice
- Comentado [LELJ14]: To define
- Comentado [LELJ15]: This is not clear and it is not the proper way to express concentrations.

243 **Treatment of human gingival fibroblasts (HGFs) with *P. gingivalis***

- Comentado [LELJ16]: Previously described

264 Human gingival fibroblasts, at a seeding density of 5×10^5 cells/well, were cultured in a Costar®
265 24-well plate (Corning Life Sciences, Corning, NY, USA) in DMEM medium at 37°C in an
266 atmosphere of 5% CO₂. After the incubation period, fresh medium without antibiotics was added
267 to HGFs, before they were treated with *P. gingivalis*. HGFs were stimulated with bacteria, at
268 multiplicities of infection (MOI) of 1:100 for 24 h, and with cystatin C at a concentration of 0.3
269 µg/mL at 37°C for 24 h, to perform cytokine assays, and evaluate ROS, and NO. Control groups
270 include HGFs without stimulation or stimulated with 100 ng/mL of LPS (LPS from *Escherichia*
271 *coli* O111:B4, Sigma Aldrich), or with 10 µg/mL of peptidoglycans (Peptidoglycan from
272 *Staphylococcus aureus*, Sigma Aldrich).

Eliminó: |
Eliminó:
Eliminó:
Eliminó:
Eliminó:
Eliminó: -

Eliminó: and
Eliminó:
Eliminó: .
Comentado [LELJ17]: How do you decide which to use?

275 Cytokine assays

276 For cytokine assays, HGFs were incubated with *P. gingivalis* (MOI 1:100) and/or with cystatin C
277 at a concentration of 0.3 µg/mL at 37°C for 24 h. Control groups included HGFs without
278 stimulation or stimulated with LPS 100 ng/mL (LPS from *Escherichia coli* O111:B4, Sigma
279 Aldrich) or with peptidoglycan 10 µg/mL (Peptidoglycan from *Staphylococcus aureus*, Sigma
280 Aldrich). ELISAs were performed to determine TNF-α, IL-1β, and IL-10, using the Ready-Set-
281 Go! ELISA kits (BD Biosciences, Cytokine ELISA Protocol, San Diego, CA, USA), following
282 the manufacturer's protocol. Dilutions were prepared in dilution buffer. Briefly, 96-well plates
283 with flat-bottom (Costar®, Corning Life Sciences) were coated with anti-human monoclonal
284 antibodies recognizing IL-1β, IL-10 or TNF-α (BD Biosciences, Pharmingen). After blocking
285 with the assay solution (PBS-0.5% casein diluted in 1 M NaOH) an overnight incubation at 4°C
286 was done in order to eliminate non-specific binding, for this 100 µL of standard TNF-α, IL-1β,
287 or IL-10 (BD Bioscience, Pharmingen) of supernatants were added. The microplate was washed
288 to remove unbound enzyme-labeled antibodies. The amount of horseradish peroxidase in each
289 well was revealed by the addition of a substrate solution. Finally, the reaction was stopped by the
290 addition of 0.18 M sulfuric acid and the plates were read at 405 nm (ELISA microplate reader,
291 Bio-Rad, Hercules, CA, USA).

Eliminó:
Eliminó:

Eliminó: ,

Eliminó: according to
Eliminó: f
Eliminó: plates
Eliminó: TNF-α, IL-1β, or IL-10
Eliminó:
Eliminó: to avoid

Eliminó: bound to
Eliminó:
Eliminó: determined
Eliminó: T

292 The cytokine concentrations were calculated by regression analysis from a standard curve.
293 The detection limit of the assay was 15 to 2000 pg/mL.

Eliminó: was

294

318 **Measurement of NO production**

319 The NO production by HGFs incubated with *P. gingivalis* and/or cystatin C at 37°C was assayed
320 by measuring the accumulation of nitrate in culture supernatants. Briefly, HGFs were stimulated
321 with *P. gingivalis* (MOI 1:100) and with 0.3 µg of cystatin C, at 37°C for 24 h. Thereafter, 100
322 µL of Griess reagent (1% sulphanilamide, 0.1% naphthylethylene diamine dihydrochloride, and
323 2.5% phosphoric acid) (Sigma Aldrich) were added at equal volumes of culture supernatants in a
324 96- well plate (Costar®, Corning Life Sciences) and left at room temperature for 30 min. The
325 absorbance of these supernatants were read at 550 nm (Multiskan SkyHigh Microplate
326 Spectrophotometer) and the nitrate concentrations were calculated from a standard curve
327 established with serial dilutions of NaNO₂ (Sigma-Aldrich) in the culture medium. Control
328 groups included HGFs without stimulation or stimulated with LPS or peptidoglycan.

329
330 **Detection of Reactive Oxygen Species (ROS)**

331 HGFs were seeded on 24-well plates (Costar®, Corning Life Sciences) at a density of (5x10⁵),
332 infected with *P. gingivalis* (MOI 1:100) and stimulated with 0.3 µg/ml of cystatin C at 37°C for
333 24 h. The cells were incubated with 100 µg/mL [2 µM/mL] of 2,7-dichlorodifluorescein
334 diacetate (H2-DCFDA) for 30 min in the dark at room temperature. Cells were rinsed twice with
335 PBS, pH 7.2 and detached from the wells with 0.25% Trypsin/EDTA (Sigma Aldrich). The
336 samples were resuspended in PBS, pH 7.2, with 1% FBS and analyzed on a FACS Canto II BD
337 Biosciences flow cytometer. Data analysis was performed using FlowJo software (USA). Control
338 groups included HGFs without stimulation or stimulated with LPS or peptidoglycan.

339
340 **Statistical analysis**

341 Experimental and control conditions were statistically compared for significance using analysis
342 of variance (ANOVA), followed by Benferroni correction. The predetermined level of
343 significance was p < 0.05. Statistical analysis was performed with the GraphPad, Prism v.6
344 software (GraphPad Software, Inc., CA, USA).

345
346 **Results**

347 **Effects of cystatin C on growth of *P. gingivalis* and viability of HGFs**

Eliminó: ¶

Eliminó:

Comentado [LELJ18]: Why not such s St Louis Missouri?

Eliminó: was

Comentado [LELJ19]: To express in units. 5x10e5/ mL, per well or what?

Eliminó:

Eliminó:

Eliminó:

Eliminó:

Eliminó:

Con formato: Izquierda

Comentado [LELJ20]: To choose the way to express this concentration, only one.

Eliminó:

Eliminó:

Eliminó: ¶

Eliminó: [2 µM/mL]

Comentado [LELJ21]: To define

Dio formato: Fuente: Negrita

360 The antimicrobial activity of cystatin C on *P. gingivalis* was analyzed in a time and dose-
361 dependent manner as shown in (Fig. 1a). It reached its maximal antimicrobial activity at 24 h
362 with concentrations between 0.1 and 0.3 µg/mL.

Eliminó:

363 The concentration of 0.3 µg/mL inhibited 75% of bacteria growth after 24h of incubation when
364 compared to the control group ($p < 0.05$). Inhibition of bacterial growth (83.3%) was observed
365 after 48 h of culture ($p < 0.05$). At a concentration of 0.9 µg/mL a marked growth inhibition was
366 observed throughout the incubation time. All the analyzed concentrations of cystatin C showed
367 no effect on the viability of HGFs cells, as illustrated in (Fig. 1b). These findings reveal the
368 antimicrobial activity of cystatin C against *P. gingivalis* and did not affect the viability of HGFs.
369 Hence, we decided to perform all the experimental assays with a cystatin C MIC at 0.3 µg/mL.

Eliminó:

370 371 **Effect of cystatin C on the production of pro- and anti-inflammatory cytokines**

372
373 TNF- α and IL-1 β were evaluated in supernatants of HGFs incubated with *P. gingivalis* and
374 cystatin C (0.3 µg/mL) for 24 h. *P. gingivalis* induced the production of 1000 pg/mL and 750
375 pg/mL of TNF- α and IL-1 β , respectively, when compared to the control group ($p = 0.0001$) (Figs
376 2a, 2b). However, when HGFs were incubated with the bacteria and cystatin C, a statistically
377 significant decrease was observed in the TNF- α ($p = 0.0001$) and IL-1 β ($p < 0.05$) productions,
378 compared to HGFs. In contrast, no changes were observed in IL-10 production by HGFs
379 incubated with *P. gingivalis* alone, when compared to controls, whereas cystatin C stimulated de
380 production and secretion of IL-10 (500 pg/mL). Furthermore, the co-incubation of *P. gingivalis*
381 with cystatin C significantly increased the production of IL-10 (900 pg/mL), when compared
382 with the control group and with HGFs infected with the bacterium ($p = 0.0001$), (Fig.2c). These
383 results suggest that cystatin C participates in the regulatory inflammatory process, by reducing
384 inflammatory cytokines and increasing anti-inflammatory cytokines.

Con formato: Izquierda

Eliminó:

Eliminó:

385 386 **Cystatin C decreases ROS and NO production on HGFs incubated with *P. gingivalis***

387 A significant increase was observed in the production of ROS and NO in HGFs incubated with
388 *P. gingivalis*, compared to the controls ($p = 0.0001$). No significant differences were observed in
389 the production of ROS in HGFs incubated with cystatin C ($p > 0.05$) (Fig.3a). In contrast, a
390 significant decrease in ROS was observed after the incubation of HGFs with *P. gingivalis* and
391 cystatin C, compared to the control ($p = 0.001$), (Fig. 3a).

Eliminó:

398 Furthermore, a significant increase of NO (9 μ M) was observed after the incubation of HGFs with
399 *P. gingivalis*, when compared with the control group ($p = 0.0001$). Yet when HGFs were incubated
400 with *P. gingivalis* and cystatin C, a decrease of NO (3 μ M) ($p = 0.001$) was observed regarding
401 the incubation with *P. gingivalis* alone (Fig. 3b).

Eliminó:

Eliminó: with regard to

402 403 Discussion

Con formato: Izquierda

404 In this study, we analyzed the antimicrobial activity of cystatin C against *P. gingivalis*, which
405 contributes to the development of chronic periodontitis. The immunological responses occurring
406 in HGFs after the infection with this key periodontal pathogen were evaluated. *P. gingivalis*
407 exhibits a variety of virulence factors that enable it to colonize oral soft tissues and evade
408 immune responses. It has been demonstrated that *P. gingivalis* triggers and suppresses the
409 immune responses in HGFs, suggesting that the pathogenic effects of *P. gingivalis* are mainly
410 related to the action of gingipains, which participate in the inflammatory and immune response
411 of HGFs (Palm, Khalaf & Bengtsson, 2015; Bengtsson, Khalaf & Palm, 2015). Additionally, *P.*
412 *gingivalis* has a direct modulatory function on the immune response of fibroblasts through the
413 catalytic activities of gingipains, targeting fibroblast-derived inflammatory mediators at the
414 protein level (Palm, Khalaf & Bengtsson, 2013). *P. gingivalis* secretes three related cysteine
415 proteases (gingipains), which constitute its main virulence factors. Two gingipains are specific
416 for Arg-Xaa peptide bonds (HRgpA and RgpB), whereas Kgp cleaves after a Lys residue
417 (Imamura, 2003). Interestingly, gingipains are involved in the disruption of host defense
418 inflammatory reactions and hinder *P. gingivalis* clearance by the immune system (Uehara et al.,
419 2008; Guo, Nguyen & Potempa, 2010). Human gingival fibroblasts play an important part in the
420 innate immune system by sensing microbial invasion and responding to it by producing and
421 secreting inflammatory mediators. HGFs recognize *P. gingivalis* during the early stages of
422 periodontitis and establish an inflammatory response in the periodontal tissue (Palm, Half &
423 Bengtsson, 2015). The secretion of TNF- α and IL-1 β by HGFs favor the recruitment of
424 macrophages and neutrophils to the site of infection, as well as the expression of MMP-1, MMP-
425 13, MMP-8, and MMP-9, which contribute to the degradation of the extracellular matrix of the
426 periodontal tissue as well as the reabsorption of bone tissue (Ara et al., 2009; Song et al., 2021;
427 Cheng et al., 2020; Franco et al., 2017; Siu et al., 2020; Menaka et al., 2009).

Eliminó:

Eliminó:

432 Interleukin-1 β (IL-1 β), belongs to the IL-1 family and plays an important role against microbial
433 infections and participates regulating innate immune and inflammatory responses. The
434 upregulation of IL-1 β during *P. gingivalis* infection suggests that IL-1 β is a critical cytokine in
435 the host's defense against *P. gingivalis* infection during the initial phases of inflammation
436 (Dinarello, 2009). In the early stages of *P. gingivalis* infection, IL-1 β plays an important role in
437 combating the invading pathogen as part of the innate immune response and participates in
438 almost all events involved in the activation and regulation of inflammation (Menu & Vince,
439 2011). This kind of inflammasome-independent IL-1 β activation can substantially contribute to
440 tissue inflammation (Latz & Xiao & Stutz, 2013).

Dio formato: Fuente: Cursiva

441 We now demonstrate that cystatin C down-regulates the production of IL-1 β and TNF- α in HFGs
442 co-incubated with *P. gingivalis*. Our finding is in accordance with the literature, where cystatin C
443 has been shown to down-regulate the production of IL-1 β and TNF- α in monocytes stimulated
444 with bacterial LPS (Gren et al., 2016). In addition to cystatin C, other salivary antimicrobial
445 peptides, such as histatin 5 and histatin 1, also down-regulate inflammatory cytokines like IL-6,
446 IL-8, IL-1 β , and TNF- α in fibroblasts and macrophages (Imatani et al., 2000; Lee et al., 2021).
447 Our data also show that cystatin C enhances IL-10 production by HFGs incubated with *P.*
448 *gingivalis*, which could represent an important mechanism to inhibit an excessive inflammatory
449 response of HFGs to the *P. gingivalis* infections. The cytokine IL-10 can inhibit pro-
450 inflammatory responses, due to its ability to reduce the production of TNF- α , IL-6, and IL-1
451 cytokines (Sun et al., 2020). Our results suggest that cystatin C could be an important
452 multifunctional modulator of the innate immune responses in HFGs.

Eliminó: I

453 In addition to cytokine production, HFGs also produce microbicidal mediators such as ROS and
454 NO, when they are infected with *P. gingivalis*. High doses of these molecules have been shown
455 to be cytotoxic to periodontal tissue (Nogueira et al., 2016), since their excessive production may
456 lead to tissue breakdown, including inhibition of energy-generating enzymes, triggering DNA
457 injury, oxidation and nitration reactions, (Wang, Huang & He, 2019; Bodis &
458 Haregewoin, 1993). ROS causes oxidative damage to proteins and DNA, it interferes with cell
459 growth, and induces apoptosis in gingival fibroblasts, causing periodontitis (Kanzaki et al., 2017;
460 Cheng et al., 2015; Tomofuji et al., 2006; Marayuma et al., 2011). In addition to the damage
461 caused by ROS, an increase of iNOS expression and NO concentration also leads to severe
462 damage related to bone resorption, as shown in an experimental rat model of periodontitis

Eliminó:

Eliminó:

Eliminó: I

467 (Wang, Huang & He 2019). Thus, many inflammatory mediators are crucial for the development
468 of early periodontal disease, where NO is one of the main inflammatory factors (Pacher
469 Beckman, & Liaudet, 2007). *P. gingivalis* induces NO production and inducible nitric oxide
470 synthase (iNOS) expression in immune and nonimmune host cells (Sun et al., 2010). Although
471 macrophages are the source of the iNOS expression, NO production is elevated in HGFs that are
472 stimulated by TNF- α , IL-1 β , and IFN- γ . NO high concentrations they have a side effect on the
473 periodontal tissue, favoring vasodilation and platelet aggregation diminish, which can contribute
474 to gingival bleeding, aside from having cytotoxic effects on the surrounding tissue, increasing
475 the severity of the periodontitis (Boutrouin et al., 2012).

476 Our data now demonstrated that *P. gingivalis* stimulates NO release by HGFs and that the co-
477 incubation of the bacterium with cystatin C significantly down-regulates both ROS and NO
478 productions. These findings are in accordance with the literature, showing that other peptides,
479 such as hBD3 and sublaicin, also reduce the production of ROS in endothelial cells and NO in
480 peritoneal macrophages, respectively (Wang, Huang & He, 2019; Bian et al., 2017). The results
481 of our study suggest that NO expression could lead to the gradual progression of periodontitis
482 after proinflammatory cytokine production by HGFs infected by *P. gingivalis* and that cystatin C
483 protects from tissue damage through the reduction of these free radicals. The importance of ROS
484 in periodontal diseases was previously demonstrated by Cheng et al, who showed that LPS from
485 *P. gingivalis* up-regulated ROS in periodontal ligament fibroblasts (Cheng et al., 2015; Goltz et
486 al., 2014). The release of inflammatory mediators including interleukins, chemokines, adhesion
487 molecules, and ROS could be triggered by bacteria LPS (Goraca et al., 2013; Melo et
488 al., 2010; Sanikidze et al., 2006; Bykov et al., 2003).

489 Antimicrobial peptides are included in the immune innate defense system in the oral cavity
490 (Greer, Zenobia & Darveau 2013). The antimicrobial peptide cystatin C belongs to the type 2
491 family of the cystatin superfamily, it is ubiquitously distributed in plants, animals, and
492 microorganisms (Shamsi & Bano, 2017). Saliva from the parotid gland of humans contain 0.9
493 $\mu\text{g}/\text{mL}$ of cystatin C (Gorr S, 2009). The main function of cystatin C is the inhibition of cysteine
494 proteases, by binding to their active sites, evading the cleavage of peptide bonds (van Wyk, et
495 al., 2016). The mechanisms leading to the reduction of the inflammatory mediators by cystatin C
496 are possibly explained by observations made with a homologous molecule, DsCistatin, isolated
497 from the tick *Dermacentor silvarum*. This peptide was shown to be internalized by endocytosis

Eliminó: ¶

Eliminó:

Eliminó:

Eliminó:

Eliminó:

Eliminó:

Eliminó: contains

Eliminó:

Eliminó: C

Eliminó:

508 in mouse macrophages stimulated with LPS from *Borrelia burgdorferi*. It reduced the
509 inflammatory cytokines IL-1 β , IFN- γ , TNF- α , and IL-6 by the degradation of the TRAF6
510 protein, thereby preventing the phosphorylation of I κ B α and the subsequent nuclear transport of
511 NF- κ B, leading to the decrease of inflammatory cytokines (Sun et al., 2018). We speculate that
512 cystatin C possibly follows this route to reduce inflammatory mediators in HGFs incubated with
513 *P. gingivalis*.

514 Our data now show that cystatin C possibly plays an important antimicrobial and anti-
515 inflammatory role that regulates the response of human gingival fibroblast towards *P. gingivalis*,
516 helping to avoid tissue damage and destruction.

517

518 **Conclusions**

519 Cystatin C exhibits a dual activity during *P. gingivalis* infection. Antimicrobial activity was
520 demonstrated without cytotoxic effects on HGFs. Furthermore, cystatin C also exhibited
521 immunomodulatory functions, decreasing the inflammatory response of fibroblasts. Knowledge
522 on the immunomodulatory properties of cystatin C could aid in the design of new therapeutic
523 approaches to improve the treatment of periodontal diseases.

524

525

526

527 **Acknowledgements**

528 We thank Drs Daniela Cortés Hernández and Dulce Verónica Rivero Gamallo for their
529 assistance in the culture of bacteria and human fibroblasts during the initial phase of the
530 study and Rocely Cervantes Sarabia for her assistance in cytotoxicity assays.

531

532 **References**

- 533 Aleksandrowicz P, Brzezińska-Błaszczyk E, Kozłowska E, Żelechowska P, Borgonovo A E,
534 & Agier J. 2021. Analysis of IL-1 β , CXCL8, and TNF- α levels in the crevicular fluid of patients
535 with periodontitis or healthy implants. *BMC oral health*, 21(1), 120.
536 <https://doi.org/10.1186/s12903-021-01478-3>
- 537
- 538 Al-Rasheeda A, Scheerens H, Srivastava A K, Rennick D M, & Tatakis D N. 2004.
539 Accelerated alveolar bone loss in mice lacking interleukin-10: late onset. *Journal of periodontal*
540 *research*, 39(3), 194–198. <https://doi.org/10.1111/j.1600-0765.2004.00724.x>
- 541
- 542 Ara T, Kurata K, Hirai K, Uchihashi T, Uematsu T, Imamura Y, Furusawa K, Kurihara S,
543 & Wang P L. 2009. Human gingival fibroblasts are critical in sustaining inflammation in

Eliminó: C

545 periodontal disease. *Journal of periodontal research*, 44(1), 21–27.
546 <https://doi.org/10.1111/j.1600-0765.2007.01041.x>
547
548 **Atanasova K, Lee J, Roberts J, Lee K, Ojcius DM & Yilmaz Ö. 2016.** Nucleoside-Diphosphate-Kinase
549 of *P. gingivalis* is Secreted from Epithelial Cells In the Absence of a Leader Sequence Through a Pannexin-
550 1 Interactome. *Scientific reports*, 6, 37643. <https://doi.org/10.1038/srep37643>
551
552 **Baek KJ, Choi Y, & Ji S. (2013).** Gingival fibroblasts from periodontitis patients exhibit
553 inflammatory characteristics in vitro. *Archives of oral biology*, 58(10), 1282–1292.
554 <https://doi.org/10.1016/j.archoralbio.2013.07.007>
555
556 **Bascones A, Gamonal J, Gomez M, Silva A, & Gonzalez M A. 2004.** New knowledge of the
557 pathogenesis of periodontal disease. *Quintessence international (Berlin, Germany : 1985)*, 35(9),
558 706–716.
559
560 **Bengtsson T, Khalaf A, & Khalaf H. 2015.** Secreted gingipains from *Porphyromonas gingivalis*
561 colonies exert potent immunomodulatory effects on human gingival fibroblasts. *Microbiological*
562 *research*, 178, 18–26. <https://doi.org/10.1016/j.micres.2015.05.008>
563
564 **Bian T, Li H, Zhou Q, Ni C, Zhang Y, & Yan F. 2017.** Human β -Defensin 3 Reduces TNF- α -
565 Induced Inflammation and Monocyte Adhesion in Human Umbilical Vein Endothelial
566 Cells. *Mediators of inflammation*, 2017, 8529542. <https://doi.org/10.1155/2017/8529542>
567
568 **Blancas B, Lanzagorta ML, Jiménez-García LF, Lara R, Molinari JL, Fernández AM. 2021.**
569 Study of the ultrastructure of *Enterococcus faecalis* and *Streptococcus mutans* incubated with
570 salivary antimicrobial peptides. *Clin Exp Dent Res*. 7(3):365-375. doi: 10.1002/cre2.430.
571
572 **Blankenvoorde MF, van't Hof W, Walgreen-Weterings E, van Steenberghe TJ, Brand HS, Veerman EC &**
573 **Nieuw Amerongen AV. 1998.** Cystatin and cystatin-derived peptides have antibacterial activity against the pathogen
574 *Porphyromonas gingivalis*. *Biological chemistry*, 379(11), 1371–1375
575
576 **Bodis S, & Haregewoin A. 1993.** Evidence for the release and possible neural regulation of nitric
577 oxide in human saliva. *Biochemical and biophysical research communications*, 194(1), 347–350.
578 <https://doi.org/10.1006/bbrc.1993.1826>
579
580 **Boutrín MC, Wang C, Aruni W, Li X, & Fletcher H M. 2012.** Nitric oxide stress resistance in
581 *Porphyromonas gingivalis* is mediated by a putative hydroxylamine reductase. *Journal of*
582 *bacteriology*, 194(6), 1582–1592. [https://doi.org/10.1128/JB.06457-](https://doi.org/10.1128/JB.06457-12)
583 Brennan PA, Thomas GJ, Langdon JD. (2003). The role of nitric oxide in oral diseases. *Arch. Oral*
584 *Biol.* 48(2) :93–10. [https://doi.org/10.1016/S0003-9969\(02\)00183-8](https://doi.org/10.1016/S0003-9969(02)00183-8)
585
586 **Bykov I, Ylipaasto P, Eerola L, & Lindros K O. 2003.** Phagocytosis and LPS-stimulated
587 production of cytokines and prostaglandin E2 is different in Kupffer cells isolated from the
588 periportal or perivenous liver region. *Scandinavian journal of gastroenterology*, 38(12), 1256–
589 1261. <https://doi.org/10.1080/00365520310007116>
590

Dio formato

Dio formato

591 **Calkins C C, Platt K, Potempa J, & Travis J. 1998.** Inactivation of tumor necrosis factor-alpha
592 by proteinases (gingipains) from the periodontal pathogen, *Porphyromonas gingivalis*.
593 Implications of immune evasion. *The Journal of biological chemistry*, 273(12), 6611–6614.
594 <https://doi.org/10.1074/jbc.273.12.6611>
595
596 **Chapple I L, Matthews J B. 2007.** The role of reactive oxygen and antioxidant species in
597 periodontal tissue destruction. *Periodontol.* 2000 43, 160–232. 10.1111/j.1600-
598 0757.2006.00178.x
599
600 **Cheng R, Choudhury D, Liu C, Billet S, Hu T, & Bhowmick N A. 2015.** Gingival fibroblasts
601 resist apoptosis in response to oxidative stress in a model of periodontal diseases. *Cell death*
602 *discovery*, 1, 15046. <https://doi.org/10.1038/cddiscovery.2015.46>
603
604 **Cheng R, Wu Z, Li M, Shao M, & Hu T. 2020.** Interleukin-1 β is a potential therapeutic target
605 for periodontitis: a narrative review. *International journal of oral science*, 12(1), 2.
606 <https://doi.org/10.1038/s41368-019-0068-8>
607
608 **Christopher J R, Ponnaiyan D, Parthasarathy H, & Tadepalli A. 2021.** Association
609 of *CST3* Gene with Its Protein: Cystatin C in Health and Severe Periodontal Disease. *Genetic*
610 *testing and molecular biomarkers*, 25(6), 405–410. <https://doi.org/10.1089/gtmb.2021.0049>
611
612 **Dinareello C A. 2009.** Immunological and inflammatory functions of the interleukin-1 family.
613 *Annual review of immunology*, 27, 519–550.
614 <https://doi.org/10.1146/annurev.immunol.021908.132612>
615
616 **Eloff J N. 1998.** A sensitive and quick microplate method to determine the minimal inhibitory
617 concentration of plant extracts for bacteria. *Planta medica*, 64(8), 711–713.
618 <https://doi.org/10.1055/s-2006-957563>
619
620 **Emani S, Gunjiganur G V, & Mehta D S. 2014.** Determination of the antibacterial activity
621 of simvastatin against periodontal pathogens, *Porphyromonas gingivalis* and *Aggregatibacter*
622 *actinomycetemcomitans*: An in vitro study. *Contemporary clinical dentistry*, 5(3), 377–382.
623 <https://doi.org/10.4103/0976-237X.137959>
624
625 **Franco C, Patricia H R, Timo S, Claudia B, & Marcela H. (2017).** Matrix Metalloproteinases
626 as Regulators of Periodontal Inflammation. *International journal of molecular sciences*, 18(2),
627 440. <https://doi.org/10.3390/ijms18020440>
628
629 **Gabay C, Lamacchia C, & Palmer G. 2010.** IL-1 pathways in inflammation and human
630 diseases. *Nature reviews. Rheumatology*, 6(4), 232–241. <https://doi.org/10.1038/nrrheum.2010.4>
631
632 **Garlet G P, Cardoso C R, Silva T A, Ferreira B R, Avila-Campos M J, Cunha F Q, & Silva**
633 **J S. 2006.** Cytokine pattern determines the progression of experimental periodontal disease

Dio formato: Inglés (americano)

634 induced by *Actinobacillus actinomycetemcomitans* through the modulation of MMPs, RANKL,
635 and their physiological inhibitors. *Oral microbiology and immunology*, 21(1), 12–20.
636 <https://doi.org/10.1111/j.1399-302X.2005.00245.x>
637
638 **Geng Y, Li L, Wang X, He F, Zhou Y, Yang M, & Xu Y. 2018.** Interleukin-10 polymorphisms
639 affect the key periodontal pathogens in Chinese periodontitis patients. *Scientific reports*, 8(1),
640 9068. <https://doi.org/10.1038/s41598-018-26236-4>
641
642 **Gözl L, Memmert S, Rath-Deschner B, Jäger A, Appel T, Baumgarten G, Götz W, & Frede**
643 **S. 2014.** LPS from *P. gingivalis* and hypoxia increases oxidative stress in periodontal ligament
644 fibroblasts and contributes to periodontitis. *Mediators of inflammation*, 2014, 986264.
645 <https://doi.org/10.1155/2014/986264>
646
647 **Gomes F I, Aragão M G, Barbosa F C, Bezerra MM, de Paulo Teixeira Pinto V, & Chaves**
648 **H V. 2016.** Inflammatory Cytokines Interleukin-1 β and Tumour Necrosis Factor- α Novel
649 Biomarkers for the Detection of Periodontal Diseases: a Literature Review. *Journal of oral &*
650 *maxillofacial research*, 7(2), e2. <https://doi.org/10.5037/jomr.2016.7202>
651
652 **Goraça A, Huk-Kolega H, Kleniewska P, Piechota-Polańczyk A, & Skibska B. 2013.** Effects
653 of lipoic acid on spleen oxidative stress after LPS administration. *Pharmacological reports : PR*,
654 65(1), 179–186. [https://doi.org/10.1016/s1734-1140\(13\)70976-9](https://doi.org/10.1016/s1734-1140(13)70976-9)
655
656 **Gorr S U. 2009.** Antimicrobial peptides of the oral cavity. *Periodontology 2000*, 51, 152–180.
657 <https://doi.org/10.1111/j.1600-0757.2009.00310.x>
658
659 **Gorr S U. 2012.** Antimicrobial peptides in periodontal innate defense. *Frontiers of oral*
660 *biology*, 15, 84–98. <https://doi.org/10.1159/000329673>
661
662 **Graves D T, Oskoui M, Volejnikova S, Naguib G, Cai S, Desta T, Kakouras A, & Jiang Y.**
663 **2001.** Tumor necrosis factor modulates fibroblast apoptosis, PMN recruitment, and osteoclast
664 formation in response to *P. gingivalis* infection. *Journal of dental research*, 80(10), 1875–1879.
665 <https://doi.org/10.1177/00220345010800100301>
666
667 **Gren S T, Janciauskiene S, Sandeep S, Jonigk D, Kvist P H, Gerwien J G, Håkansson K, &**
668 **Grip O. 2016.** The protease inhibitor cystatin C down-regulates the release of IL- β and TNF- α in
669 lipopolysaccharide activated monocytes. *Journal of leukocyte biology*, 100(4), 811–822.
670 <https://doi.org/10.1189/jlb.5A0415-174R>
671
672 **Greer A, Zenobia C, & Darveau R P. 2013.** Defensins and LL-37: a review of function in the
673 gingival epithelium. *Periodontology 2000*, 63(1), 67–79. <https://doi.org/10.1111/prd.12028>
674
675 **Gutiérrez-Venegas G, Maldonado-Frías S, Ontiveros-Granados A, & Kawasaki-Cárdenas**
676 **P. 2005.** Role of p38 in nitric oxide synthase and cyclooxygenase expression, and nitric oxide and

Código de campo cambiado

Código de campo cambiado

677 PGE2 synthesis in human gingival fibroblasts stimulated with lipopolysaccharides. *Life*
678 *sciences*, 77(1), 60–73. <https://doi.org/10.1016/j.lfs.2004.12.015>

679
680 **Guo Y, Nguyen K A, & Potempa J. 2010** Dichotomy of gingipains action as virulence factors:
681 from cleaving substrates with the precision of a surgeon's knife to a meat chopper-like brutal
682 degradation of proteins. *Periodontology 2000* 54(1) 15–44. [https://doi.org/10.1111/j.1600-](https://doi.org/10.1111/j.1600-0757.2010.00377.x)
683 [0757.2010.00377.x](https://doi.org/10.1111/j.1600-0757.2010.00377.x)

684
685 **Hariyani N, Nur HA, Al-Junaid M, Fadhila O, Indah BT. 2021.** Mouse periodontitis models using whole
686 *Porphyromonas gingivalis* bacteria induction. *Saudi Dental Journal*.
687 <https://doi.org/10.1016/j.sdentj.2021.08.001>

688
689 **Henry L G, McKenzie R M, Robles A, & Fletcher H M (2012).** Oxidative stress resistance in
690 *Porphyromonas gingivalis*. *Future microbiology*, 7(4), 497–512.
691 <https://doi.org/10.2217/fmb.12.17>

692
693 **Herath T, Darveau R P, Seneviratne CJ, Wang C Y, Wang Y, & Jin L. 2016.** Heterogeneous
694 *Porphyromonas gingivalis* LPS modulates immuno-inflammatory response, antioxidant defense
695 and cytoskeletal dynamics in human gingival fibroblasts. *Scientific reports*, 6, 29829.
696 <https://doi.org/10.1038/srep29829>

697
698 **How KY, Song K P, & Chan KG. 2016.** *Porphyromonas gingivalis*: An Overview of
699 Periodontopathic Pathogen below the Gum Line. *Frontiers in microbiology*, 7, 53.
700 <https://doi.org/10.3389/fmicb.2016.00053>

701
702 **Imamura T. 2003.** The role of gingipains in the pathogenesis of periodontal disease. *Journal of*
703 *Periodontology*, 74 (1), 111- 118, <https://doi.org/10.1902/jop.2003.74.1.111>

704
705 **Imatani T, Kato T, Minaguchi K, & Okuda K. 2000.** Histatin 5 inhibits inflammatory cytokine
706 induction from human gingival fibroblasts by *Porphyromonas gingivalis*. *Oral microbiology and*
707 *immunology*, 15(6), 378–382. <https://doi.org/10.1034/j.1399-302x.2000.150607.x>

708
709 **Jadaun G P, Agarwal C, Sharma H, Ahmed Z, Upadhyay P, Faujdar J, Gupta A K, Das R.,**
710 **Gupta P, Chauhan D S, Sharma V D, & Katoch V M. 2007.** Determination of ethambutol MICs
711 for *Mycobacterium tuberculosis* and *Mycobacterium avium* isolates by resazurin microtitre
712 assay. *The Journal of antimicrobial chemotherapy*, 60(1), 152–155.
713 <https://doi.org/10.1093/jac/dkm117>

714
715 **Jia L, Han N, Du J, Guo L, Luo Z, & Liu Y. (2019).** Pathogenesis of Important Virulence Factors
716 of *Porphyromonas gingivalis* via Toll-Like Receptors. *Frontiers in cellular and infection*
717 *microbiology*, 9, 262. <https://doi.org/10.3389/fcimb.2019.00262>

718
719 **Kanzaki H, Wada S, Narimiya T, Yamaguchi Y, Katsumata Y, Itohiya K, Fukaya S,**
720 **Miyamoto Y and Nakamura Y. 2017.** Pathways that Regulate ROS Scavenging Enzymes, and
721 Their Role in Defense Against Tissue Destruction in Periodontitis. *Front. Physiol.* 8:351. doi:
722 10.3389/fphys.2017.00351

723

Código de campo cambiado

- 724 **Kirkwood KL, Cirelli JA, Rogers JE, & Giannobile W V. 2007.** Novel host response
725 therapeutic approaches to treat periodontal diseases. *Periodontology* 2000, 43, 294–315.
726 <https://doi.org/10.1111/j.1600-0757.2006.00166.x>
727
- 728 **Kobayashi-Sakamoto M, Isogai E, & Hirose K. 2003.** *Porphyromonas gingivalis* modulates the
729 production of interleukin 8 and monocyte chemotactic protein 1 in human vascular endothelial
730 cells. *Current microbiology*, 46(2), 109–114. <https://doi.org/10.1007/s00284-002-3782-x>
731
- 732 **Könönen E, Gursoy M, & Gursoy U K. 2019.** Periodontitis: A Multifaceted Disease of Tooth-
733 Supporting Tissues. *Journal of clinical medicine*, 8(8), 1135. <https://doi.org/10.3390/jcm8081135>
734
- 735 **Kratzer E, Tian Y, Sarich N, Wu T, Meliton A, Leff A, & Birukova A A. 2012.** Oxidative
736 stress contributes to lung injury and barrier dysfunction via microtubule destabilization. *American*
737 *journal of respiratory cell and molecular biology*, 47(5), 688–697.
738 <https://doi.org/10.1165/rcmb.2012-0161OC>
739
- 740 **Latz E, Xiao T S, & Stutz A. 2013.** Activation and regulation of the inflammasomes. *Nature*
741 *reviews. Immunology*, 13(6), 397–411. <https://doi.org/10.1038/nri3452>
742
- 743 **Lee Ik, Lee Mj & Jang HS. 2013.** The interrelationship between human gingival fibroblast
744 differentiation and cultivating time. *Tissue Eng Regen Med* 10, 60–64 (2013).
745 <https://doi.org/10.1007/s13770-013-0371-y>
746
- 747 **Lee S M, Son K N, Shah D, Ali M, Balasubramaniam A, Shukla D, & Aakalu V K 2021.**
748 Histatin-1 Attenuates LPS-Induced Inflammatory Signaling in RAW264.7
749 Macrophages. *International journal of molecular sciences*, 22(15), 7856.
750 <https://doi.org/10.3390/ijms22157856>
751
- 752 **Liang W, & Diana J. 2020.** The Dual Role of Antimicrobial Peptides in Autoimmunity. *Frontiers*
753 *in immunology*, 11, 2077. <https://doi.org/10.3389/fimmu.2020.02077>
754
- 755 **Liu J, Wang Y, Shi Q, Wang X, Zou P, Zheng M, & Luan Q. 2022.** Mitochondrial DNA Efflux
756 Maintained in Gingival Fibroblasts of Patients with Periodontitis through ROS/mPTP
757 Pathway. *Oxidative medicine and cellular longevity*, 2022, 1000213.
758 <https://doi.org/10.1155/2022/1000213>
759
- 760 **McFarland J. 1907** Nephelometer: An Instrument for Estimating the Number of Bacteria in
761 Suspensions Used for Calculating the Opsonic Index and for Vaccines. *Journal of the American*
762 *Medical Association*, 14, 1176-1178. <http://dx.doi.org/10.1001/jama.1907.25320140022001f>
763
- 764 **Mei F, Xie M, Huang X, Long Y, Lu X, Wang X, & Chen L. 2020.** *Porphyromonas*
765 *gingivalis* and Its Systemic Impact: Current Status. *Pathogens (Basel, Switzerland)*, 9(11), 944.
766 <https://doi.org/10.3390/pathogens9110944>
767
- 768 **Melo E S, Barbeiro H V, Ariga S, Goloubkova T, Curi R, Velasco I T, Vasconcelos D, &**
769 **Soriano F G. 2010.** Immune cells and oxidative stress in the endotoxin tolerance mouse model.

Código de campo cambiado

Dio formato

770 *Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e*
771 *biologicas*, 43(1), 57–67. <https://doi.org/10.1590/s0100-879x2009007500027>
772
773 **Mendez KN, Hoare A, Soto C, Bugueño I, Olivera M, Meneses C, Pérez-Donoso JM, Castro-Nallar**
774 **E & Bravo D . 2019.** Variability in Genomic and Virulent Properties of *Porphyromonas gingivalis* Strains
775 Isolated From Healthy and Severe Chronic Periodontitis Individuals. *Frontiers in cellular and infection*
776 *microbiology*, 9, 246. <https://doi.org/10.3389/fcimb.2019.00246>
777
778 **Maruyama T, Tomofuji T, Endo Y, Irie K, Azuma T, Ekuni D, Tamaki N, Yamamoto T, &**
779 **Morita M. 2011.** Supplementation of green tea catechins in dentifrices suppresses gingival
780 oxidative stress and periodontal inflammation. *Archives of oral biology*, 56(1), 48–53.
781 <https://doi.org/10.1016/j.archoralbio.2010.08.015>
782
783 **Menu P, & Vince J E. 2011.** The NLRP3 inflammasome in health and disease: the good, the bad
784 and the ugly. *Clinical and experimental immunology*, 166(1), 1–15. [https://doi.org/10.1111/j.1365-](https://doi.org/10.1111/j.1365-2249.2011.04440.x)
785 [2249.2011.04440.x](https://doi.org/10.1111/j.1365-2249.2011.04440.x)
786
787 **Mickels N, McManus C, Massaro J, Friden P, Braman V, D'Agostino R, Oppenheim F,**
788 **Warbington M, Dibart S, Van Dyke T. 2001.** Clinical and microbial evaluation of a histatin-
789 containing mouthrinse in humans with experimental gingivitis. *J Clin Periodontol*. May;28(5):404-
790 10. doi: 10.1034/j.1600-051x.2001.028005404.x
791
792 **Nogueira T P, Gonçalves BF, Gabriela S D, Hebling J, de Souza CC. 2016.** Functional
793 Differences In Gingival Fibroblasts Obtained from Young and Elderly Individuals. *Braz. Dent. J.*
794 27 (5) <https://doi.org/10.1590/0103-6440201600993>
795
796 **Pacher P, Beckman J S, & Liaudet L. 2007.** Nitric oxide and peroxynitrite in health and disease.
797 *Physiological reviews*, 87(1), 315–424. <https://doi.org/10.1152/physrev.00029.2006>
798
799 **Palm E, Khalaf H, & Bengtsson T. 2013.** *Porphyromonas gingivalis* downregulates the immune
800 response of fibroblasts. *BMC microbiology*, 13, 155. <https://doi.org/10.1186/1471-2180-13-155>
801
802 **Palm E, Khalaf H, & Bengtsson T. 2015.** Suppression of inflammatory responses of human
803 gingival fibroblasts by gingipains from *Porphyromonas gingivalis*. *Molecular oral*
804 *microbiology*, 30(1), 74–85. <https://doi.org/10.1111/omi.12073>
805
806 **Pan W, Wang Q, & Chen Q. 2019.** The cytokine network involved in the host immune response
807 to periodontitis. *International journal of oral science*, 11(3), 30. [https://doi.org/10.1038/s41368-](https://doi.org/10.1038/s41368-019-0064-z)
808 [019-0064-z](https://doi.org/10.1038/s41368-019-0064-z)
809
810 **Rafiei M, Kiani F, Sayehmiri F, Sayehmiri K, Sheikhi A & Zamanian Azodi M. 2017.** Study
811 of *Porphyromonas gingivalis* in periodontal diseases: A systematic review and meta-
812 analysis. *Medical journal of the Islamic Republic of Iran*, 31, 62.
813 <https://doi.org/10.18869/mjiri.31.62>
814

Código de campo cambiado

815 **Ramadan DE, Hariyani N, Indrawati R, Ridwan R D, & Diyatri I. 2020.** Cytokines and
816 Chemokines in Periodontitis. *European journal of dentistry*, 14(3), 483–495.
817 <https://doi.org/10.1055/s-0040-1712718>
818

819 **Sanikidze T V, Tkhilava N G, Papava M B, Datunashvili I V, Gongadze M T,**
820 **Gamrekelashvili D D, & Bakhutashvili V I. 2006.** Role of free nitrogen and oxygen radicals in
821 the pathogenesis of lipopolysaccharide-induced endotoxemia. *Bulletin of experimental biology*
822 *and medicine*, 141(2), 211–215. <https://doi.org/10.1007/s10517-006-0130-3>
823

824 **Shamsi A, & Bano B. 2017.** Journey of cystatins from being mere thiol protease inhibitors to at
825 heart of many pathological conditions. *International journal of biological macromolecules*, 102,
826 674–693. <https://doi.org/10.1016/j.ijbiomac.2017.04.071>
827

828 **Smith PC, Martínez C, Martínez J, & McCulloch C A. 2019.** Role of Fibroblast Populations in
829 Periodontal Wound Healing and Tissue Remodeling. *Frontiers in physiology*, 10, 270.
830 <https://doi.org/10.3389/fphys.2019.00270>
831

832 **Sosroseno W, Bird P S & Seymour G J. 2009.** Nitric oxide production by a human osteoblast
833 cell line stimulated with *Aggregatibacter actinomycetemcomitans* lipopolysaccharide. *Oral*
834 *Microbiol Immunol* 24 (1) 50–55 doi: 10.1111/j.1399-302X.2008.00475.x.
835

836 **Song H K, Noh E , Kim J M, You Y O, Kwon K B, & Lee Y R. 2021.** *Evodiae fructus* Extract
837 Inhibits Interleukin-1 β -Induced MMP-1, MMP-3, and Inflammatory Cytokine Expression by
838 Suppressing the Activation of MAPK and STAT-3 in Human Gingival Fibroblasts In
839 Vitro. *Evidence-based complementary and alternative medicine : eCAM*, 2021, 5858393.
840 <https://doi.org/10.1155/2021/5858393>
841

842 **Sun W, Wu J, Lin L, Huang Y, Chen Q, & Ji Y. 2010.** *Porphyromonas gingivalis* stimulates
843 the release of nitric oxide by inducing expression of inducible nitric oxide synthases and inhibiting
844 endothelial nitric oxide synthases. *Journal of periodontal research*, 45(3), 381–388.
845 <https://doi.org/10.1111/j.1600-0765.2009.01249.x>
846

847 **Sun T, Wang F, Pan W, Wu Q, Wang J, & Dai J. 2018.** An Immunosuppressive Tick Salivary
848 Gland Protein DsCystatin Interferes With Toll-Like Receptor Signaling by Downregulating
849 TRAF6. *Frontiers in immunology*, 9, 1245. <https://doi.org/10.3389/fimmu.2018.01245>
850

851 **Sun L, Girnary M, Wang L, Jiao Y, Zeng E, Mercer K, Zhang J, Marchesan J T, Yu N, Moss**
852 **K, Lei Y L, Offenbacher S, & Zhang S. 2020.** IL-10 Dampens an IL-17-Mediated Periodontitis-
853 Associated Inflammatory Network. *Journal of immunology (Baltimore, Md. : 1950)*, 204(8),
854 2177–2191. <https://doi.org/10.4049/jimmunol.1900532>
855

856 **Tomofuji T, Azuma T, Kusano H, Sanbe T, Ekuni D, Tamaki N, Yamamoto T, &**
857 **Watanabe T. 2006.** Oxidative damage of periodontal tissue in the rat periodontitis model:
858 effects of a high-cholesterol diet. *FEBS letters*, 580 (15), 3601–3604.
859 <https://doi.org/10.1016/j.febslet.2006.05.041>

860
861 **Torbjörn B, Atika K, Hazem Khalaf. 2015.** Secreted gingipains from *Porphyromonas gingivalis*
862 colonies exert potent immunomodulatory effects on human gingival fibroblasts. *Microbiological*
863 *Research*. 178 (2015) :18-26. <http://dx.doi.org/10.1016/j.micres.2015.05.00>
864
865 **Uehara A, Naito M, Imamura T, Potempa J, Travis J, Nakayama K, and Takada, H. 2008.**
866 Dual regulation of interleukin-8 production in human oral epithelial cells upon stimulation with
867 gingipains from *Porphyromonas gingivalis*. *J. Med. Microbiol.* 57, 500–507
868 **van Winkelhoff, AJ, Loos BG, van der Reijden WA, van der Velden U. 2002**
869 *,Porphyromonas gingivalis, Bacteroides forsythus* and other putative periodontal pathogens in
870 subjects with and without periodontal destruction. *Journal of Clinical Periodontology*.
871 29(11):1023-1028. <https://doi.org/10.1034/j.1600-051X.2002.291107.x>
872
873 **van Wyk S G, Kunert K J, Cullis C A, Pillay P, Makgopa M E, Schlüter U, & Vorster B J**
874 **.2016.** Review: The future of cystatin engineering. *Plant science : an international journal of*
875 *experimental plant biology*, 246, 119–127. <https://doi.org/10.1016/j.plantsci.2016.02.016>
876
877 **Vray B, Hartmann S, & Hoebeke J. 2002.** Immunomodulatory properties of cystatins. *Cellular*
878 *and molecular life sciences : CMLS*, 59(9), 1503–1512. [https://doi.org/10.1007/s00018-002-](https://doi.org/10.1007/s00018-002-8525-4)
879 [8525-4](https://doi.org/10.1007/s00018-002-8525-4)
880
881 **Wang H, Zhou H, Duan X, Jotwani R, Vuddaraju H, Liang S, Scott DA, & Lamont R J.**
882 **2014.** *Porphyromonas gingivalis*-induced reactive oxygen species activate JAK2 and regulate
883 production of inflammatory cytokines through c-Jun. *Infection and immunity*, 82(10), 4118–4126.
884 <https://doi.org/10.1128/IAI.02000-14>
885
886 **Wang H, Ai L, Zhang Y, Cheng J, Yu H, Li C, Zhang D, Pan Y, Lin L. 2018.** The Effects of
887 Antimicrobial Peptide Nal-P-113 on Inhibiting Periodontal Pathogens and Improving Periodontal
888 Status. *Biomed Res Int*.15; 2018:1805793. doi: 10.1155/2018/1805793
889
890 **Wang Y, Huang X, & He F 2019.** Mechanism and role of nitric oxide signaling in
891 periodontitis,.*Exp Ther Med* 18, 1503-1512
892
893 **Xie H, Wu L, Chen X, Gao S, Li H, Yuan Y, Liang J, Wang X, Wang S, Xu C, Chu L, Zhan B, Zhou**
894 **R & Yang X. 2021.** *Schistosoma japonicum* Cystatin Alleviates Sepsis Through Activating Regulatory
895 Macrophages. *Frontiers in cellular and infection microbiology*, 11, 617461.
896 <https://doi.org/10.3389/fcimb.2021.617461>
897
898 **Zhu C, Zhao Y, Wu X, Qiang C, Liu J, Shi J, Gou J, Pei D, Li A. 2020.** The therapeutic role
899 of baicalein in combating experimental periodontitis with diabetes via Nrf2 antioxidant signaling
900 pathway. *J Periodontal Res.* 55(3):381-391. doi: 10.1111/jre.12722.
901
902 **Zumft W. G. (2002).** Nitric oxide signaling and NO dependent transcriptional control in bacterial
903 denitrification by members of the FNR-CRP regulator family. *Journal of molecular microbiology*
904 *and biotechnology*, 4(3), 277–286.

905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941

ADDITIONAL INFORMATION AND DECLARATIONS

Funding Ana María Fernández Presas

This work was supported by grant # IN218419, from PAPITT, DGAPA, UNAM, Mexico City, and partially by Universidad Anahuac México Campus Norte . Blanca Esther Blancas-Luciano is supported by CONACYT grant # 424031 for her doctoral studies. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Grant Disclosures The following grant information was disclosed by the authors:

PAPITT, DGAPA, UNAM, Mexico City: #IN218419.

CONACYT: # 424031

Competing Interests The authors declare there are no competing interests.

Author Contributions

Blanca Blancas, Jaime Zamora, Adriana Remigio, and Delgado Dominguez participate in the conceptualization, study design, conducted all the experiments, Data curation, and reviewed drafts of the paper
r, Leyva-Huerta ER, Portilla-Robertson J, participate in the conceptualization, data curation and reviewed drafts of the paper.

I. Becker was involved in the concept of the study, Supervision, Visualization, critically revised the manuscript, and approved the final draft,

A.M Fernández participated in Conceptualization, study design, conducted experiments, supervision, visualization interpreted the data, drafted the manuscript, approved the final draft. and acquired the funding.

Data Availability

The following information was supplied regarding data availability: